Hikma Pharmaceuticals PLC 2014 SR
The report highlights Hikma's commitment to providing high-quality, affordable medicines while managing its environmental and social impact. In 2014, the company launched 75 products and received 263 approvals, focusing on chronic diseases like cancer and diabetes. Key initiatives included strengthening the Injectables business through acquisitions and promoting ethical practices via anti-bribery training for over 600 managers. Environmental efforts were marked by a 10% reduction in Scope 1 emissions and participation in the Carbon Disclosure Project. The company also supported local communities through medical donations to Gaza and health awareness campaigns.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2014
Type: SR
Pages: 9
Back to company
Hikma Pharmaceuticals PLC
Sustainability Report
The report highlights Hikma's commitment to providing high-quality, affordable medicines while managing its environmental and social impact. In 2014, the company launched 75 products and received 263 approvals, focusing on chronic diseases like cancer and diabetes. Key initiatives included strengthening the Injectables business through acquisitions and promoting ethical practices via anti-bribery training for over 600 managers. Environmental efforts were marked by a 10% reduction in Scope 1 emissions and participation in the Carbon Disclosure Project. The company also supported local communities through medical donations to Gaza and health awareness campaigns.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Employees